While individuals taking semaglutide can still contract COVID-19, they had a 33% lower chance of dying from the sickness, according to a study published by the Journal of the American College of Cardiology at the end of August.
The studies also show that semaglutide can reduce a patient’s risk of serious heart events such as heart attacks and strokes.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.